Navigation Links
3SBio Inc. Announces Change to the Board of Directors
Date:2/19/2008

SHENYANG, China, Feb. 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that Mr. Mingde Yu has been appointed as an independent director of the Company. Mr. Yu succeeds Mr. Guanjin Hu, a director of 3SBio since August 2006, who has tendered his resignation as a result of his increasing official work commitments. The appointment of Mr. Yu took effect on February 15, the effective date of Mr. Hu's resignation.

Dan Lou, Chairman of 3SBio, commented, "On behalf of the Board, I would like to welcome Mingde Yu to 3SBio. Mr. Yu brings to 3SBio a wealth of knowledge and experience gained over a long and distinguished career in the pharmaceutical industry in China. He will be a vital resource to the Board as we continue to grow the business and create shareholder value. I would also like to thank Mr. Guanjin Hu for his contributions to the Company's success, and wish him all the best in his future endeavors."

Mr. Yu, 62, has extensive experience in manufacturing and distribution management in the pharmaceutical industry in China. He has held a number of senior positions both in the government and the private sectors, including as the Chief Technology Officer and the Head of Manufacturing at both Liaoning Fuxi Pharmaceutical Co. and Fuxi Traditional Chinese Medicine Co., Bureau Chief of the Fuxi City Food & Drug Administration, Bureau Chief of the Liaoning Provincial Food & Drug Administration, Drug Department Chief of the Economic Operations Bureau of the State Economic and Trade Committee, and Vice-Bureau Chief of Economic Operations Department of the National Development Reform Committee. Mr. Yu is currently the honorary Chairman and Director of the Beijing Pharmaceutical Group and is the Vice Committee Chair for the China Pharmaceutical Enterprises Administrative Association and China Medical Entrepreneur Association. In addition, Mr. Yu holds senior consultancy roles with the China Chemical Drug Association and the National Pharmaceutical Industry & Commerce Association.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

For more information, please contact:

Investor Contact:

Kevin Teo, CFO

3SBio Inc.

Tel: +86-24-2581-1820

Investor Relations(HK):

Ruby Yim

Taylor Rafferty

Tel: +852-3196-3712

Investor Relations(US):

Mahmoud Siddig

Taylor Rafferty

Tel: +1-212-889-4350

Media Contact:

John Dooley

Taylor Rafferty

Tel: +1-212-889-4350


'/>"/>
SOURCE 3SBio Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. Schedules 2007 Third Quarter Earnings Release On Tuesday, November 13, 2007
4. 3SBio Inc. To Present at the 19th Annual Piper Jaffray Health Care Conference
5. 3SBio Inc. Announces Appointment of Kevin Sow Peng Teo as Chief Financial Officer
6. 3SBio Inc. to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. 3SBio Inc. Schedules 2007 Fourth Quarter and Full Year Earnings Release on Wednesday, February 20, 2008
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... COLORADO SPRINGS, CO , March 29, 2017 /PRNewswire/ - Last year,s ... who support kratom are not the only efforts active to generate ... that substitute opiate based pharmaceutical drugs in the healthcare market place. ... Earlier this ... U.S. based developer and distributor of pharmaceutical and nutritional products, announced ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... to announce that Nerium International Mexico has been approved as an active member ... to achieve satisfaction and protection among distributers and consumers in relationship marketing. This ...
(Date:3/29/2017)... , March 29, 2017  Halozyme Therapeutics, ... oncology and drug-delivery therapies, today announced that an ... and Drug Administration voted 11 to 0 that ... skin) injection was favorable for patients in the ... lymphoma and chronic lymphocytic leukemia. The FDA action ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... is exhibiting in booth 513 at the Association of Community Cancer Centers (ACCC) ... March 29-31. , CANCERSCAPE unites key stakeholders from leading national organizations to ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... ARMONK, N.Y. and PORTLAND, Ore. ... IBM ) and the Avamere Family of Companies (Avamere ... Care) today announced a six-month research study that will ... caregivers improve eldercare at senior living and health centers. ... facilities, Avamere hopes to gain insights into physical and ...
(Date:2/16/2017)... 16, 2017  Genos, a community for personal ... has received Laboratory Accreditation from the College of ... to laboratories that meet stringent requirements around quality, ... processes. "Genos is committed to maintaining ... We,re honored to be receiving CAP accreditation," said ...
Breaking Biology News(10 mins):